Introduction {#s1}
============

Twenty years since its publication, the Institute of Medicine's report, *To Err is Human: Building a Safer Health System*,[@R1] has generated much attention towards identifying safety issues in healthcare. Quality-related events (QREs) are those medication incidents that reach the patient as well as incidents that are intercepted prior to dispensing.[@R2]

While considerable progress has been in documenting the magnitude of QREs in the inpatient setting, less is known about QREs in community pharmacy. In 2018, Campbell and colleagues coauthored a systematic review and meta-analysis of community pharmacy errors.[@R3] Only nine studies met the inclusion criteria, the majority of which were of short duration (all but one were 40 weeks or less) and included a small number of prescriptions (all but one included less than 13 000 prescriptions). Significant heterogeneity was identified among the studies.

To address this knowledge gap, we analysed QREs reported by community pharmacies in one Canadian province over a 7-year period and identified the drugs associated with harm.

Methods {#s2}
=======

Since 2010, all community pharmacies in Nova Scotia, Canada have been required by the provincial pharmacy regulator to report all QREs anonymously to a national incident data repository (housed by the Institute for Safe Medication Practices Canada).[@R4] QREs reported by all Nova Scotia community pharmacies from 1 October 2010 to 30 June 2017 were included in this retrospective analysis. A descriptive analysis was performed on QREs with respect to the drugs involved and whether the QREs resulted in harm. The Anatomical Therapeutic Chemical Classification System was used to classify the active ingredients of the drugs and to group them into categories for the purpose of this analysis. Patients and the public were not involved in the design of this study. A complete methodology description has been previously published.[@R5]

Results {#s3}
=======

The 301 pharmacies in Nova Scotia reported 98 097 QREs during the 7-year period. Of these QREs, almost 1% (928) were associated with patient harm, where 90% (839 out of 928) were reported as mild harm.[@R5]

Levothyroxine sodium was the drug most commonly associated with a QRE, accounting for 2433 QREs or 2.34% of all QREs ([table 1](#T1){ref-type="table"}). It was closely followed by amoxicillin, which was reported in 2361 QREs or 2.27% of all QREs.

###### 

Top 20 medications with respect to the number of reported QREs

  Medication                                  ATC classification   Number (%) of QREs
  ------------------------------------------- -------------------- --------------------
  Levothyroxine sodium                        H03AA01              2433 (2.34)
  Amoxicillin                                 J01CA04              2361 (2.27)
  Rosuvastatin                                C10AA07              1905 (1.84)
  Lorazepam                                   N05BA06              1840 (1.77)
  Hydromorphone                               N02AA03              1826 (1.76)
  Metoprolol                                  C07AB02              1786 (1.72)
  Salbutamol                                  R03AC02              1745 (1.68)
  Metformin                                   A10BA02              1568 (1.51)
  Rabeprazole                                 A02BC04              1459 (1.41)
  Zopiclone                                   N05CF01              1374 (1.32)
  Atorvastatin                                C10AA05              1290 (1.24)
  Citalopram                                  N06AB04              1261 (1.21)
  Prednisone                                  H02AB07              1254 (1.21)
  Naproxen                                    M01AE02              1236 (1.19)
  Clonazepam                                  N03AE01              1175 (1.13)
  Codeine, combinations excl. Psycholeptics   N02AA59              1163 (1.12)
  Hydrochlorothiazide                         C03AA03              1158 (1.12)
  Venlafaxine                                 N06A×16              1143 (1.10)
  Cefalexin                                   J01DB01              1127 (1.09)
  Pantoprazole                                A02BC02              1044 (1.01)
  Total                                       --                   103 812**\***

\*Total of all reported medications in QREs (excluding free-form entry of medication name). The reporter can input more than one medication per QRE; hence, the total number of QREs in this table is greater than what is shown in the results section.

ATC, Anatomical Therapeutic Chemical; QREs, quality-related events.

Levothyroxine sodium was the drug most commonly associated with a QRE causing harm (46 cases). Regarding levothyroxine, of the 46 harm cases, 44 (96%) were reported as mild harm and 2 (4%) were reported as moderate harm. Citalopram (27 cases), hydromorphone (25 cases) and warfarin (22 cases) were also commonly associated with harm. Together, these four drugs were responsible for 11.3% (120 out of 1064 cases) of all QREs that resulted in harm.

[Table 2](#T2){ref-type="table"} displays the top 20 medications by proportion of QREs with harm (minimum of 10 QREs reported with harm). One in 10 (10.33%) QREs reported with methadone resulted in harm, representing the greatest proportion of QREs with harm. Regarding methadone, of the 19 harm cases, 18 (95%) were reported as mild harm and 1 (5%) was reported as moderate harm. Methadone was followed by risperidone (3.51%), warfarin (2.95%) and morphine (2.82%) as far as QRE cases associated with harm.

###### 

Top 20 medications by proportion of QREs with harm (minimum of 10 QREs reported with harm)

  Medication                          ATC classification   Number (%) of QREs with harm   Number (%) of QREs   Proportion of QREs with harm (%)
  ----------------------------------- -------------------- ------------------------------ -------------------- ----------------------------------
  Methadone                           N07BC02              19 (1.79)                      184 (0.18)           10.33
  Risperidone                         N05A×08              11 (1.03)                      313 (0.30)           3.51
  Warfarin                            B01AA03              22 (2.07)                      746 (0.72)           2.95
  Morphine                            N02AA01              16 (1.50)                      568 (0.55)           2.82
  Atenolol                            C07AB03              14 (1.32)                      544 (0.52)           2.57
  Citalopram                          N06AB04              27 (2.54)                      1261 (1.21)          2.14
  Norgestimate and oestrogen          G03AB11              10 (0.94)                      528 (0.51)           1.89
  Levothyroxine sodium                H03AA01              46 (4.32)                      2433 (2.34)          1.89
  Gliclazide                          A10BB09              13 (1.22)                      694 (0.67)           1.87
  Ramipril                            C09AA05              14 (1.32)                      778 (0.75)           1.80
  Sulfamethoxazole and trimethoprim   J01EE01              13 (1.22)                      808 (0.78)           1.61
  Furosemide                          C03CA01              15 (1.41)                      1024 (0.99)          1.46
  Hydromorphone                       N02AA03              25 (2.35)                      1826 (1.76)          1.37
  Venlafaxine                         N06A×16              14 (1.32)                      1143 (1.10)          1.22
  Amlodipine                          C08CA01              12 (1.13)                      988 (0.95)           1.21
  Sertraline                          N06AB06              10 (0.94)                      845 (0.81)           1.18
  Naproxen                            M01AE02              13 (1.22)                      1236 (1.19)          1.05
  Prednisone                          H02AB07              13 (1.22)                      1254 (1.21)          1.04
  Pantoprazole                        A02BC02              10 (0.94)                      1044 (1.01)          0.96
  Rosuvastatin                        C10AA07              18 (1.69)                      1905 (1.84)          0.94
  Total                               --                   1064\*                         103 812†             --

\*Total of all reported medications in QREs with harm (excluding free-form entry of medication name); the reporter can input more than one medication per QRE; hence, the total number of QREs associated with patient harm in this table is greater than what is shown in the results section.

†Total of all reported medications in QREs (excluding free-form entry of medication name). The reporter can input more than one medication per QRE; hence, the total number of QREs in this table is greater than what is shown in the results section.

ATC, Anatomical Therapeutic Chemical; QREs, quality-related events.

Discussion {#s4}
==========

This study presents the first large-scale, longitudinal analysis of drugs associated with community pharmacy QREs in one entire jurisdiction over an extended period of time. By identifying the drugs most commonly associated with QREs that result in harm, proactive strategies can be developed to reduce future events. When planning and prioritising quality improvement interventions in community pharmacy, it is important to consider the frequency and the severity of harm associated with the QREs.

Strengths of this study include the large number of QREs collected (nearly 100 000) over a 7-year period from all pharmacy types (independent, chain and so on) in every setting (urban, rural and so on) in one jurisdiction. Limitations include the small number of QREs causing harm, which precluded testing for differences across types of pharmacies or locations. Finally, Nova Scotia is a small province. Recently, other provinces have begun implementing new requirements for medication incident reporting in community practice,[@R6] which could facilitate the completion of a larger analysis in the future. Nevertheless, this analysis provides valuable insight into the drugs associated with QREs in community pharmacy practice.
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